Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Intracortical GABAergic dysfunction in patients with fatigue and dysexecutive syndrome after COVID-19

Viviana Versace a,*, Luca Sebastianelli a, Davide Ferrazzoli a, Roberto Romanello a, Paola Ortelli a, Leopold Saltuari a, Alessia D’Acunto b, Francesco Porrazzini b, Valentina Ajello c, Antonio Oliviero d, Markus Kofler e,1, Giacomo Koch b,f,1

aDepartment of Neurorehabilitation, Hospital of Vipiteno (SABES-ASDAA), Vipiteno-Sterzing, Italy
bNon-Invasive Brain Stimulation Unit/Department of Behavioral and Clinical Neurology, Santa Lucia Foundation IRCCS, Rome, Italy
cDepartment of Cardiac Anesthesia, Tor Vergata University Hospital, Rome, Italy
dFENNSI Group, Hospital Nacional de Parapléjicos, Servicio de Salud de Castilla La Mancha, Toledo, Spain
eDepartment of Neurology, Hochzirl Hospital, Zirl, Austria
fDepartment of Neuroscience and Rehabilitation, University of Ferrara, Italy

Objective: A high proportion of patients experience fatigue and impairment of cognitive functions after coronavirus disease 2019 (COVID-19). Here we applied transcranial magnetic stimulation (TMS) to explore the activity of the main inhibitory intracortical circuits within the primary motor cortex (M1) in a sample of patients complaining of fatigue and presenting executive dysfunction after resolution of COVID-19 with neurological manifestations.

Methods: Twelve patients who recovered from typical COVID-19 pneumonia with neurological complications and complained of profound physical and mental fatigue underwent, 9 to 13 weeks from disease onset, a psychometric evaluation including a self-reported fatigue numeric-rating scale (FRS, Fatigue Rating Scale) and the Frontal Assessment Battery (FAB). Intracortical activity was evaluated by means of well-established TMS protocols including short-interval intracortical inhibition (SICI), reflecting GABAA-mediated inhibition, long-interval intracortical inhibition (LICI), a marker of GABA B receptor activity, and short-latency afferent inhibition (SAI) that indexes central cholinergic transmission. TMS data were compared to those obtained in a control group of ten healthy subjects (HS) matched by age, sex and education level.

Results: Post-COVID-19 patients reported marked fatigue according to FRS score (8.1 ± 1.7) and presented pathological scores at the FAB based on Italian normative data (12.2 ± 0.7). TMS revealed marked reduction of SICI, and disruption of LICI as compared to HS. SAI was also slightly diminished.

Abbreviations: TMS, transcranial magnetic stimulation; GABA, gamma aminobutyric acid; SICI, short-interval intracortical inhibition; LICI, long-interval intracortical inhibition; SAI, short-latency afferent inhibition; FRS, Fatigue Rating Scale; FAB, frontal assessment battery.

* Corresponding author at: Department of Neurorehabilitation, Hospital of Vipiteno (SABES-ASDAA), Margarethenstr. 24, I-39049 Vipiteno- Sterzing (BZ), Italy.
E-mail address: viviana.versace@sabes.it (V. Versace).
1 These authors share senior authorship.

https://doi.org/10.1016/j.clinph.2021.03.001
1388-2457/© 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.
1. Introduction

Patients affected by coronavirus disease 19 (COVID-19) may develop a wide spectrum of neurological manifestations affecting central and peripheral nervous system that have been linked to hyper-inflammatory reaction to “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) infection (Ellul et al., 2020). However, autoimmune pathology following dysregulation of the host immune defence and direct infection of the nervous system via hematogenous or neuronal retrograde routes cannot be excluded (Ellul et al., 2020). In 64 patients with COVID-19–associated neurologic manifestations, 36 presented with abnormal MRI, most frequently ischemic strokes, leptomeningeal enhancement, and encephalitis (Kremer et al., 2020). Eight patients with COVID-19–associated encephalopathy had anti–SARS-CoV-2 antibodies detected in their cerebrospinal fluid (Alexopoulos et al., 2020). Even after the resolution of the acute disease, patients manifest a plethora of long-lasting symptoms. Among them, a high proportion of individuals (up to 53.1%) experience mental and physical fatigue (Carfi et al., 2020; El Sayed et al., 2020; Ferraro et al., 2021; Ortelli et al., 2020; Townsend et al., 2020) and present with dysexecutive syndrome mainly concerning attentive deficits and reduced cognitive control (Helms et al., 2020; Ortelli et al., 2020). Despite this evidence, impact of COVID-19 on cortical activity has so far not been studied. Here we used transcranial magnetic stimulation (TMS) to investigate the functional integrity of intracortical inhibitory circuits within the primary motor cortex (M1) in a sample of patients who recovered from COVID-19 with neurological complications and presented fatigue and dysexecutive syndrome as long-lasting sequelae. Paired-pulse TMS protocols allow indeed exploring inhibitory or excitatory intracortical networks depending on the intensity and interstimulus interval (ISI) used. The role of inhibitory neuronal networks on physiological brain functions has been thoroughly demonstrated ( Tremblay et al., 2016 ).

Maladaptation of cortical processes related to degeneration of inhibitory GABAergic intracortical circuits within the M1 has been reported in various affections of the central nervous system inducing central fatigue. Short-interval intracortical inhibition (SICI) was found to be reduced in patients with multiple sclerosis ( Liepert et al., 2005 ), encephalopathy following primary biliary cirrhosis ( McDonald et al., 2010 ), and amyotrophic lateral sclerosis ( Vucic et al., 2011 ), who experienced profound fatigue. Furthermore, impairment of SICI and of long-interval intracortical inhibition (LICI) was a specific finding in frontotemporal dementia, in which executive dysfunction is a prominent feature ( Benussi et al., 2017 ).

We hypothesized that fatigue and deficit of frontal cognitive functions in post- COVID-19 patients could be underlined by functional impairment of the main inhibitory circuits in the M1 and searched therefore, by means of TMS, for specific alteration of related neurophysiological markers. We applied a well-established paired–pulse TMS protocol to study SICI and intracortical facilitation (ICF) ( Kuji et al., 1993 ). SICI is thought to represent GABA A-receptor-mediated fast inhibitory post-synaptic potentials (IPSPs) in corticospinal neurons ( Ziemann et al., 2015 ). ICF reflects mainly glutamatergic intracortical excitatory transmission although it is a net facilitation that amalgamates inhibition from the tail of the GABA A-receptor-mediated SICI ( Ziemann et al., 2015 ). We also assessed LICI ( Valls-Solé et al., 1992 ), which is considered to be a phenomenon dependent on slow IPSPs mediated through GABA A-receptors ( Ziemann et al., 2015 ). Finally, we explored short-latency afferent inhibition (SAI), a marker of inhibitory sensorimotor integration that depends mainly on the excitatory effect of cholinergic thalamocortical projections on the inhibitory GABAergic cortical network ( Alle et al., 2009 ).

2. Methods

2.1. Participants

We studied twelve patients (2 female; age 67 ± 9.6 years; 11 right-handers; education level 11.8 ± 3.5 years) who recovered from COVID-19 pneumonia (confirmed by molecular nasopharyngeal swab test and by chest-computer tomography) with disparate neurological complications (critical illness neuropathy and myopathy, Guillain–Barré syndrome, encephalopathy and stroke) at post-acute stage, 9 to 13 weeks after disease onset, at the end of the neurorehabilitation period.

Ten healthy subjects (HS) matched by age, sex, and education level were recruited as control group (3 females; age 61 ± 8.2 years; 10 right-handers; education level 12.8 ± 3.8 years).

During the acute infection, COVID-19 patients sustained bilateral severe pneumonia, prolonged intensive care treatment, and a hyper-inflammatory state, as demonstrated by both markedly elevated C-reactive protein (CRP) and interleukine-6 (IL-6) serum levels.

At the time of the study they had almost recovered from their neurological symptoms but complained of profound fatigue.

Further inclusion criteria were: a) absence of neurological disorders prior to COVID-19, b) absence of prior or current diagnosis of psychiatric, endocrine, metabolic or cardiopulmonary conditions related to fatigue, c) absence of dyspnoea or other long-lasting sequelae of interstitial COVID-19 pneumonia, d) absence of anemia, e) no treatment with corticosteroids, antihistaminic, antihypertensive, diuretic, or hypnotic drugs at the time of study.

2.2. Psychometric evaluation

Post-COVID-19 patients performed self-evaluation of perceived psycho-physical fatigue during the preceding week by means of a single numeric rating scale, the Fatigue Rating Scale (FRS, 0: no fatigue; 10: extreme fatigue, cut-off for abnormality: 6) ( Mordillo-Mateos et al., 2019 ).

They also underwent evaluation of executive functions by means of the Frontal Assessment Battery (FAB) ( Dubois et al., 2000 ), consisting of six tasks: conceptualization and abstract reasoning through a similarities judgment task; mental flexibility through a phonetic-cue word generation task; motor programming and executive control of action through Luriás series reproduction
task: resistance to interference through a go/no-go task; inhibitory control and self-regulation through a conflicting instruction task, and environmental autonomy through the prehension behavior evaluation. Each item provides a score ranging from 0 to 3, for a total score of eighteen. FAB scores corrected for age and education lower than 13.48 were reported abnormal, based on Italian normative data (Appollonio et al., 2005).

2.3. TMs

During the experiments, the patients were sitting comfortably in an armchair with their eyes open.

First, we recorded motor evoked potentials (MEPs) in the relaxed first dorsal interosseous (FDI) muscle. TMS was delivered over the left primary motor hand area through a tangentially oriented 7 cm figure-of-eight coil connected via a Bistim module with two Magstim 200 stimulators (Magstim Company, Whitland, Dyfed, UK) and placed over the optimal site for eliciting MEPS in the contralateral FDI muscle. The coil position was continuously monitored during the entire experiment.

The resting motor threshold (RMT) was defined as the lowest TMS intensity (expressed in percentage of the maximum stimulator output) that evoked MEPS of at least 50 μV peak-to-peak amplitude in five of ten successive trials (Rossini et al., 2015).

Then we evaluated SICI at 2 and 3 ms interstimulus intervals (ISIs) and ICF at ISI 10 and 15 ms (Kujirai et al., 1993). The stimulation intensity of the conditioning stimulus was set at 70% RMT. The stimulation intensity of the test stimulus was set at 130% RMT and adjusted to elicit stable MEPS of approximately 1 mV peak-to-peak amplitude.

Smaller but stable MEPS were accepted in those patients presenting neuropathy or myopathy (Table 1).

Subsequently, we evaluated LICI at ISI 50 and 100 ms (Valls-Solé et al., 1992). The stimulation intensity both of the conditioning and test stimulus was set at 130% RMT.

Finally, we assessed SAI in order to evaluate motor cortex inhibition induced by sensory afferents. The conditioning stimulus to the ulnar nerve at the wrist (at an intensity just above motor threshold for evoking a visible twitch of the interossei muscles) preceded the TMS by two different ISIs (+0 and + 4 ms, determined relative to the latency of the N20 component of the somatosensory evoked potentials) (Di Lazzaro et al., 2007, Tokimura et al., 2000).

The intensity of the TMS test pulse over M1 was adjusted to elicit stable MEPS of approximately 1 mV peak-to-peak amplitude. The stimulation intensity of the test stimulus was set at 130% RMT. The intensity of the TMS test pulse over M1 was adjusted to elicit stable MEPS of approximately 1 mV peak-to-peak amplitude in the relaxed FDI. We recorded somatosensory evoked potentials and measured N20 onset latency as previously described (Cruccu et al., 2008).

In all paradigms, ten stimuli were delivered for each ISI and twenty for the test condition in a pseudo-randomized sequence, considered to be a reasonable number of trials in a population MEP amplitude analysis (Ammann et al., 2020).

Responses were amplified with a Digitimer D440-4 (Digitimer Ltd., Welwyn Garden City, UK), at a sampling rate of 5 kHz, filtered at 20 and 2000 Hz, and fed to a computer using SIGNAL software (CED, Cambridge, UK). For all protocols, the amplitude of the conditioned responses was expressed as a percentage of the corresponding mean unconditioned response.

2.4. Statistics

For SICI-ICF, a two-factor repeated-measures ANOVA was performed with between-subjects factor GROUP (2 levels: patients, HS) and within-subjects factor ISI (4 levels: 2, 3, 10, and 15 ms). For both, LICI and SAI, respective two-factor repeated-measures ANOVAs were performed with between-subjects factor GROUP (2 levels: patients, HS) and within-subjects factor ISI (LICI: 50 and 100 ms; SAI: N20 + 0 and N20 + 4 ms).

Sphericity of data was assessed according to Mauchly, and when violated, Greenhouse–Geisser correction was applied accordingly. Significant main effects were followed-up with unpaired t tests.

We finally performed a correlation analysis with non-parametric Spearman-rho testing to account for the small number of items. We analysed possible relations among the percent change in patients’ conditioned MEP size at each ISI of the SICI-ICF, LICI, and SAI tests with individual FRS and FAB scores. A p value < 0.05 was considered significant.

2.5. Standard protocol approvals and patient consents

The study was approved by Human Research Ethics Committee of the Province of Bolzano, Italy (65–2020).

Written informed consent was obtained from all participants, who provided authorization for disclosure of any information that may be published.

3. Results

Patients and controls tolerated the procedures well. Table 1 summarizes demographic, clinical, laboratory, neuropsychological and neurophysiological data.

All patients reported marked fatigue on the FRS (mean score 8.1 ± 1.7). Moreover they presented diminished executive functions, as documented by abnormal scores corrected for age and education on the FAB (12.2 ± 0.7) (Appollonio et al., 2005).

The results of the various TMS protocols are shown in Table 2 and Fig. 1.

Repeated-measures ANOVA performed on the SICI-ICF data showed a significant main effect of ISI (F1,811.36,619 = 22.770; p < 0.001; η2 = 0.532) and a significant GROUP × ISI interaction (F1,811.36,619 = 5.615; p = 0.009; η2 = 0.219). Post-hoc analysis showed less SICI at ISI 2 ms (p < 0.001) and 3 ms (p < 0.01) in patients vs. HS (Fig. 1A). For LICI, repeated-measures ANOVA revealed a significant main effect of GROUP (F1,197.58 = 19.075; p < 0.001; η2 = 0.488) but not of ISI, nor an interaction of GROUP × ISI. Post-hoc analysis revealed significantly less LICI at ISI N20 + 100 ms (p = 0.008) and 100 ms (p < 0.001) in patients vs. HS (Fig. 1B).

For SAI, repeated-measures ANOVA depicted a significant main effect of GROUP (F1,20 = 5.612; p = 0.028; η2 = 0.219), but not of ISI, nor an interaction of GROUP × ISI. Post-hoc analysis revealed significantly less SAI at ISI N20 + 0 ms (p = 0.003) in patients vs. HS, while the difference did not reach statistical significance at ISI N20 + 4 ms (Fig. 1C).

The correlation analysis highlighted a negative association (ρ = -0.645, p = 0.024) between conditioned MEP size at ISI N20 + 0 ms in the SAI protocol and the patients’ FAB scores.

4. Discussion

The present findings provide neuropsychological evidence of severe impairment of GABA-ergic intracortical circuits in patients who recovered from COVID-19 with various central and peripheral neurological manifestations and who presented fatigue and impairment of executive functions.

Compared to HS, post-COVID-19 patients exhibited reduced inhibition within the M1 as evidenced by disruption of GABA A mediated SICI, at ISI 2 ms and 3 ms, and of GABA Aα mediated LICI, at ISI 50 ms and 100 ms.

ICF, which is thought to largely reflect excitatory glutamatergic transmission through the NMDA receptor, was not affected.
| Patient | Age [years] | Sex | Diagnosis | Clinical features at admission in neurorehabilitation | Clinical features at the time of TMS study | COVID-19 duration until TMS study [weeks] | Peak IL-6 level [pg/ml] | Peak CRP level [mg/l] | RMT [% MSO] | AMT [% MSO] | MEP Amplitude (mean of 5 trials) [mV] | FRS | FAB |
|---------|-------------|-----|-----------|------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------|----------------------|-------------|-------------|---------------------------------------|------|-----|
| 1       | 65          | M   | CINM      | Moderate flaccid tetraparesis, areflexia; deep sensory disturbances in lower limbs | Fatigue; dysexecutive syndrome           | 11                                        | 401                    | 18.7                 | 42          | 39          | 1.4                                   | 7    | 12.4 |
| 2       | 60          | M   | CINM      | Flaccid tetraparesis, muscle atrophy, areflexia    | Mild distal paresis MRC 4/5; fatigue; dysexecutive syndrome | 10                                        | 555                    | 15.9                 | 50          | 46          | 0.4                                   | 10   | 12.5 |
| 3       | 62          | M   | CIN       | Predominantly distal tetraparesis, hyporeflexia; anosmia | Severe cognitive impairment; dysphagia; anosmia | 11                                        | 225                    | 17.1                 | 39          | 35          | 0.9                                   | 10   | 13.0 |
| 4       | 71          | M   | Encephalopathy | Predominantly distal tetraparesis, areflexia | Severe multidomain cognitive impairment with predominant dysexecutive syndrome; fatigue; anosmia | 9                                         | 635                    | 25.2                 | 40          | 38          | 0.6                                   | 6    | 10.9 |
| 5       | 79          | M   | GBS (AIDP); mild cognitive impairment | Predominantly distal tetraparesis, areflexia; mild superficial and deep sensory disturbances; deficit in attentional processes and impulse control; anosmia | Severe dysexecutive syndrome; fatigue; anosmia | 12                                        | 214                    | 39.3                 | 38          | 35          | 1.9                                   | 9    | 11.5 |
| 6       | 75          | F   | Stroke (rMCA) | Mild left hemiparesis with hemisensory loss; left hemispatial neglect | Mild distal paresis in left upper limb (MRC 4/5); dysexecutive syndrome; fatigue. | 12                                        | N/A                    | 22.4                 | 47          | 44          | 0.4                                   | 6    | 11.7 |
| 7       | 48          | M   | Myopathy  | Limb-girdle muscle atrophy and paresis; mild myalgia | Mild proximal paresis (MRC 4/5); dysexecutive syndrome; fatigue. | 13                                        | 6386                   | 20.1                 | 50          | 46          | 0.5                                   | 6    | 12.9 |
| 8       | 56          | M   | Myopathy  | Limb-girdle muscle atrophy and paresis; myalgia; anosmia; dysgeusia | Dysexecutive syndrome; fatigue. | 13                                        | 2418                   | 34.2                 | 40          | 37          | 0.6                                   | 10   | 13.1 |
| 9       | 70          | M   | GBS (AMAN) | Predominantly distal tetraparesis, areflexia | Mild distal paresis MRC 4/5; fatigue; dysexecutive syndrome | 10                                        | 688                    | 18.9                 | 52          | 49          | 0.5                                   | 8    | 12.4 |
| 10      | 61          | F   | Encephalopathy | Behavioural changes; primary insomnia, fatigue; anosmia | Dysexecutive syndrome; fatigue. | 12                                        | 271                    | 25.7                 | 55          | 48          | 2.0                                   | 10   | 11.9 |
| 11      | 77          | M   | Myopathy  | Limb-girdle muscle atrophy and paresis; myalgia | Mild proximal paresis (MRC 4/5); dysexecutive syndrome; fatigue. | 13                                        | 1251                   | 30.4                 | 41          | 38          | 0.4                                   | 9    | 12.9 |
| 12      | 80          | M   | Encephalopathy | Severe cognitive impairment; anosmia | Severe multidomain cognitive impairment with predominant dysexecutive syndrome; fatigue; anosmia | 12                                        | 129                    | 23.0                 | 42          | 38          | 1.3                                   | 6    | 11.5 |

TMS, transcranial magnetic stimulation; CRP, c-reactive protein; IL-6, interleukin 6; RMT, resting motor threshold; AMT, active motor threshold; MEP, motor evoked potential; MSO, maximum stimulator output; CINM, critical illness neuropathy and myopathy; CIN, critical illness neuropathy; GBS, Guillain-Barré syndrome; AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; rMCA, right middle cerebral artery; FRS, fatigue rating scale; FAB, frontal assessment battery, scores corrected for age and education lower than 13.48 are abnormal, based on Italian normative data (Appollonio et al., 2005).
GABA is the principal inhibitory neurotransmitter in the human nervous system and plays a fundamental role in nearly all neuronal coding and processing throughout the brain. SICI and LICI are impaired in patients with frontotemporal dementia, presenting executive dysfunction (Benussi et al., 2017). Different cognitive abilities, mainly executive functions, are sensitive to cerebral GABA concentrations in the frontal cortex (Sumner et al., 2010; Porges et al., 2017). Impaired GABAergic cortical activity could underlie the dysexecutive syndrome common to all patients presented here, regardless of the type of initial neurological complication.

SICI was reported to be reduced in central nervous system disorders inducing chronic fatigue (Liepert et al., 2005; McDonald et al., 2010; Vucic et al., 2011). Interestingly, the same post-COVID-19 patients presented in this study showed, after a fatiguing pinching task, lack of post-exercise depression of MEPs and abnormal prolongation of cortical silent period duration (Ortelli et al., 2020). These findings may reflect the impairment of inhibitory circuits within M1 demonstrated here, with a subsequent alteration of post-exhaustion inhibition of corticormotor excitability.

Neuroinflammation is common to a broad spectrum of neurological disorders (Brambilla, 2019) and may affect GABAergic transmission in neurological disorders (Heneka et al., 2015). The reported patients showed during the acute phase of COVID-19 markedly increased CRP and IL-6 serum levels (Table 1), reliable markers of systemic inflammation. Peripheral cytokines can enter the brain and activate the microglia and the astrocytes inducing neural cytokines release and resulting in brain inflammation (Harry and Kraft, 2008). COVID-19-associated neuroinflammation could be the underpinning of the observed alteration in M1 circuits. On the other hand, prolonged cerebral hypoxia due to SARS-CoV-2-associated pulmonary pathology may also have contributed to the observed phenomenon. Notably, SICI was reduced in patients with chronic obstructive pulmonary disease (Oliviero et al., 2002).

Compared to HS, SAI mechanisms were also significantly reduced in post-COVID-19 patients at ISI N20 + 0 ms, with a similar, but non-significant reduction at N20 + 4 ms. SAI evaluates motor cortex inhibition induced by sensory afferents through inhibitory connections from the primary somatosensory cortex to M1. Both, ISI N20 + 0 ms (Tokimura et al., 2000) and N20 + 4 ms (Di Lazzaro et al., 2007) were previously demonstrated to be effective for strong SAI induction. Reduced excitatory cholinergic projections to M1 GABAergic interneurons could account in part for the observed reduction of GABA networks activity, since SAI is considered to act under the control of SICI circuit (Alle et al., 2009). As a relevant co-finding, there was a negative association between conditioned MEP size at ISI N20 + 0 ms and FAB score (the smaller the conditioned MEPs, i.e., the more efficient SAI, the better the cognitive performance).

SAI reduction was previously found during repetitive non-fatiguing movements inducing MEP depression (Miyaguchi et al., 2017). Furthermore, abnormal SAI findings concurring with central cholinergic dysfunction have been related to dementia (Nardone et al., 2011) and to olfactory dysfunction in idiopathic Parkinson’s disease (Versace et al., 2017).

Taken together, the present findings point towards a general reduction of cortical GABAergic and - to a lesser extent - cholinergic activity in post-COVID-19 patients. This alteration could underlie both the reduced cognition and the abnormal fatigue perception and could represent one of the possible mechanisms of COVID-19-related neurotoxicity. TMS may therefore represent a useful diagnostic tool in post-COVID-19 patients suffering from fatigue or cognitive disturbances.

Despite limitations – e.g., the small sample size with sequelae of inhomogeneous neurological affections and the lack of direct detection of inflammatory markers in the patients’ cerebrospinal fluid - the present study documents for the first time reduced
They also thank Mrs. Ellen Quirbach for language editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors thank all the study participants and their families. They also thank Mrs. Ellen Quirbach for language editing.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

Alexopoulos H, Magira E, Bitzogli K, Kafasi N, Vlachoyiannopoulos P, Tzioufas A, et al. Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients. Neuroul Neuroimunol Neuroinfamnn 2020;7(6):e893.

Alle H, Heidegger T, Kriváneková L, Ziemann U. Interactions between short-interval intracortical inhibition and short-latency afferent inhibition in human motor cortex. J Physiol 2009;587:5163–76.

Amman C, Guida P, Caballero-Insaurriaga J, Pineda-Pardo JA, Oliveira A, Foffani G. A framework to assess the impact of number of trials on the amplitude of motor evoked potentials. Sci Rep 2020;10(1):21422.

Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, et al. The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 2005;26(2):108–16.

Benussi A, Di Lorenzo F, Dell’Era V, Cosseddu M, Alberici A, Caratozzolo S, et al. Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia. Neurology 2017;89(7):663–72.

Brambilla R. Neuroinflammation, the thread connecting neurological disorders. Acta Neuropathol 2019;137(5):689–91.

Carfi A, Bernabei R, Landi F, Genelli against C-P-ACSG. persistent symptoms in patients after acute COVID-19. JAMA 2020;324(6):603–5.

Cruccu G, Aminoff MJ, Curio G, Guerini JM, Kalkgi R, Mauguiere F, et al. Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol 2008;119(8):1705–19.

Di Lazzaro V, Pilato F, Dileone M, Profice P, Ranieri F, Ricci V, et al. Segregating two inhibitory circuits in human motor cortex at the level of GABAA receptor subtypes: A TMS study. Clin Neurophysiol 2007;118(10):2207–14.

Dubois B, Slachekvsky A, Litvan I, Pillon B. TMS: a frontal assessment battery at bedside. Neurology 2000;55(11):1621–6.

El Sayed S, Shokry D, Gomaa SM. Post-COVID-19 fatigue and anhedonia: A cross-sectional study and their correlation to post-recovery period. Neuropsychopharmacol Rep 2020. [https://doi.org/10.1002/npr2.12154.

Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol 2020;19(9):767–83.

Ferraro F, Calafiore D, Dambrosio F, Guida R, de Sire A. COVID-19 related fatigue: Which role for rehabilitation in post-COVID-19 patients? A case series. J Med Virol 2021;93(4):1896–9.